OTONOMY, INC.
DelistedCIK 1493566fmd_14PFKNJXA4RCF12QEQSDD33SGGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2022, 40 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 1 | 1 | 1 | 1 | 0 | 0 |
| Cost of revenue | – | – | 0 | 0 | 2 | 3 | 1 | 1 | 1 | 0 |
| Gross profit | – | – | – | – | (1) | (2) | (0) | (0) | (1) | (0) |
| Research and development | 9 | 16 | 32 | 39 | 61 | 43 | 32 | 33 | 28 | 35 |
| Selling, general and administrative | – | – | – | 23 | 50 | 47 | 20 | 12 | 15 | 15 |
| Total operating expenses | 11 | 20 | 40 | 62 | – | – | – | – | – | – |
| Operating income | (11) | (20) | (40) | (62) | (111) | (91) | (52) | (45) | (43) | (50) |
| Interest expense | 0 | 3 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | 3 | 0 | (3) | 0 | 1 | 1 | 2 | 0 | (1) | (2) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (8) | (20) | (43) | (62) | (111) | (90) | (50) | (45) | (45) | (51) |
| Net income to common shareholders | (8) | (20) | (43) | (62) | (111) | – | – | – | – | – |